STO:GENO
Genovis AB · STO · Healthcare · SEK · FY for 2025
Figures on this page computed 2026-11-08 13:09 UTC
Last close
n/aSEK
Market data
58.6xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- computed
- Computed from the filing for 2025
9.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
18.2%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
23.6%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
0.52Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- computed
Price is the furthest below its sector's middle: 0.13 against 0.36 on the market's range.
- Growth16.1%62 of 100, above its sector
- Returns on capital9.7%68 of 100, above its sector
- Margins21.3%71 of 100, above its sector
- Price58.6x13 of 100, below its sector
- Safety0.5273 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
All from 100
lens 2 of 9Sales
6958530
2016-12-31 to 2025-12-31100 at the start695
Shares in issue
1411410
2016-12-31 to 2025-12-31100 at the start141
- Profit, where the first year is 100: n/aNot enough filed years carry this line for it to be drawn. No line is drawn flat in its place.
Sales is at 695, Shares in issue is at 141, against 100 in 2016.
Sales is at 695, Shares in issue is at 141, against 100 in 2016.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2025
Sales, where the first year is 100695
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- SEK
Profit, where the first year is 100n/a
Not held.
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- SEK
Shares in issue, where the first year is 100141
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- SEK